SO

Sabah Oney

Chief Executive Officer at stealth biotech

San Francisco Bay Area

Overview 

Sabah Oney is currently the CEO of a stealth biotech company in the San Francisco Bay Area with a strong background in biotechnology, oncology, and business development. Notable career highlights include serving as Chief Business Officer at Alector and leading global sales and business development at Ariosa Diagnostics, which was later acquired by Roche.

Work Experience 

stealth biotech

  • Chief Executive Officer

    2023 - Current

V

Vilya

  • Co-Founder, Interim CEO, Member Board of Directors

    2022

AV

ARCH Venture Partners

  • Venture Partner

    2021

ARCH is a venture firm that focuses on life science discoveries to prevent, detect, and cure disease.

archventure.com
A

Alector

  • Chief Business Officer

    2018 - 2021

    Areas of responsibility include: • Finance: Leading multiple private and public fundraising rounds totaling >$570M, including the IPO in 2019 • Partnering and business development: Including a $1.3B global partnership with AbbVie • Public facing functions: Including PR and IR • Facilities, IT: Including Alector’s new 105,000 sq ft HQ in South San Francisco

  • Vice President, Business Development and Operations

    2016 - 2018

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.

Raised $319,500,000.00 from Hercules Capital.

alector.com

Ariosa Diagnostics [Acquired by Roche]

  • Head of Global Sales and Business Development

    2015 - 2016

  • Director of Business Development

    2012 - 2016

G

Genentech

  • MBA Intern

    2011 - 2011

    Pipeline & Portfolio Planning (PPP) M.B.A. Intern Partnered with PPP Senior Director to formulate mid- to long-term China corporate strategy, focusing on target market and growth forecasts Diligenced scientific and financial prospects of eight start-up biotechnology companies; presented recommendations to BD oncology head and team for consideration as potential acquisition targets Evaluated project return metrics (ROI) of early stage pipeline, resulting in recommendations to improve decision making

Genentech specializes in genetic testing and personalized medicine.

gene.com

b3 bio, Inc

  • Senior Scientist

    2008 - 2010

    Involved in the establishment of the application of b3 bio's technology, leading to partnership with a major pharmaceutical company Partnered with the C.E.O. for business planning and developing mid- to long- term company strategy Coordinated a team of scientists through the conception and development of the scientific projects at b3 bio

Education 

Articles About Sabah

Relevant Websites